Trials / Completed
CompletedNCT01143337
Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis
A Multicenter Randomized, Double-blind, Placebo-controlled Study of MP-435 in Combination With MTX in Patients With Rheumatoid Arthritis - Exploratory Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the Efficacy, Safety, and Pharmacokinetics of MP-435 administered for 12 weeks in subjects with rheumatoid arthritis (RA) on stable doses of Methotrexate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-435(dose1) + Methotrexate | MP-435 dose1 + stable weekly dose of Methotrexate |
| DRUG | Placebo + Methotrexate | Placebo + stable weekly dose of Methotrexate |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2010-06-14
- Last updated
- 2026-01-06
- Results posted
- 2014-10-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01143337. Inclusion in this directory is not an endorsement.